Active Humoral Response Reverts Tumorigenicity through Disruption of Key Signaling Pathway

Area of Science:

• Oncology
• Immunology
• Vaccine Development

Background:

• Monoclonal antibodies (mAbs) are key cancer therapeutics but face limitations in cost and duration.
• Interleukin-17 receptor B (IL-17RB) is a target for cancer therapy, with mAbs intercepting its signaling pathway.
• There is a need for economical and sustainable cancer treatments.

Purpose of the Study:

• To develop a novel peptide cancer vaccine as a cost-effective and durable alternative to mAbs.
• To investigate the therapeutic potential of an IL-17RB-targeting vaccine.
• To reproduce the anti-cancer effects of IL-17RB targeting mAbs through active immunity.

Main Methods:

• Synthesized multiple epitope peptides conjugated onto the CRM197 carrier protein to create the vaccine.
• Utilized mass spectrometry and immunoassay to standardize hapten density and optimize vaccine design.
• Evaluated vaccine efficacy in an orthotopically transplanted syngeneic mouse 4T1 tumor model.

Main Results:

• The peptide cancer vaccine was successfully prepared and characterized.
• Vaccine administration demonstrated therapeutic mitigation of primary tumor growth.
• The vaccine also showed efficacy in reducing distant metastasis in preclinical models.

Conclusions:

• A novel peptide cancer vaccine targeting IL-17RB was developed and characterized.
• This vaccine shows promise as a sustainable and affordable cancer therapeutic.
• Preclinical studies indicate significant anti-tumor and anti-metastatic effects.